The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2026 | Updated IMWG myeloma response criteria: insights and practical challenges
Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Vienna, Austria, shares insights into the updated International Myeloma Working Group (IMWG) response criteria, noting that while they clarify response definitions, practical challenges remain unresolved. Prof. Ludwig highlights that the introduction of composite measurable residual disease (MRD) negativity and the requirement for serological assessment after each cycle may introduce feasibility challenges, and notes the remaining requirement for 24-hour urine testing. This interview took place at the 12th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
